Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $240 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $240.
September 12, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Alnylam Pharmaceuticals and maintained a price target of $240.
The reiteration of a 'Buy' rating by a respected analyst like Joseph Stringer is a positive signal for Alnylam Pharmaceuticals. The maintained price target of $240 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100